Dr. John F. Bohnsack
Pediatrics (Pediatric Rheumatology Physician)
100 N Medical Dr
Salt Lake City, UT 84113
Who else practices at this address →
Salt Lake County includes primary care (36% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Rheumatology Physician primary
UT license 177835-1205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $161,309 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric Participants with Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis TRILOGY
Janssen Research & Development, LLC - A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)
Janssen Research & Development, LLC - An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT01357668
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.